Varenicline

For smoking cessation

J. Rao, Pinakini K. Shankar

Research output: Contribution to journalReview article

6 Citations (Scopus)

Abstract

Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine and also reduces the rewarding effects of nicotine obtained from smoking in patients who lapse. Clinical trials have demonstrated superior efficacy of this drug over Bupropion-SR for achieving abstinence from smoking, and Varenicline has also been shown to significantly delay smoking relapse. As the latest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of Varenicline has been reviewed in this paper.

Original languageEnglish
Pages (from-to)162-164
Number of pages3
JournalKathmandu University Medical Journal
Volume7
Issue number26
Publication statusPublished - 01-04-2009
Externally publishedYes

Fingerprint

Smoking Cessation
Nicotine
Bupropion
Smoking
Nicotinic Receptors
Substance Withdrawal Syndrome
Pharmaceutical Preparations
Clinical Trials
Safety
Recurrence
Varenicline
Therapeutics

All Science Journal Classification (ASJC) codes

  • Medicine(all)

Cite this

Rao, J., & Shankar, P. K. (2009). Varenicline: For smoking cessation. Kathmandu University Medical Journal, 7(26), 162-164.
Rao, J. ; Shankar, Pinakini K. / Varenicline : For smoking cessation. In: Kathmandu University Medical Journal. 2009 ; Vol. 7, No. 26. pp. 162-164.
@article{2019d17ffa894b8ba733a8986dc4df90,
title = "Varenicline: For smoking cessation",
abstract = "Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine and also reduces the rewarding effects of nicotine obtained from smoking in patients who lapse. Clinical trials have demonstrated superior efficacy of this drug over Bupropion-SR for achieving abstinence from smoking, and Varenicline has also been shown to significantly delay smoking relapse. As the latest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of Varenicline has been reviewed in this paper.",
author = "J. Rao and Shankar, {Pinakini K.}",
year = "2009",
month = "4",
day = "1",
language = "English",
volume = "7",
pages = "162--164",
journal = "Kathmandu University Medical Journal",
issn = "1812-2027",
publisher = "Kathmandu University",
number = "26",

}

Rao, J & Shankar, PK 2009, 'Varenicline: For smoking cessation', Kathmandu University Medical Journal, vol. 7, no. 26, pp. 162-164.

Varenicline : For smoking cessation. / Rao, J.; Shankar, Pinakini K.

In: Kathmandu University Medical Journal, Vol. 7, No. 26, 01.04.2009, p. 162-164.

Research output: Contribution to journalReview article

TY - JOUR

T1 - Varenicline

T2 - For smoking cessation

AU - Rao, J.

AU - Shankar, Pinakini K.

PY - 2009/4/1

Y1 - 2009/4/1

N2 - Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine and also reduces the rewarding effects of nicotine obtained from smoking in patients who lapse. Clinical trials have demonstrated superior efficacy of this drug over Bupropion-SR for achieving abstinence from smoking, and Varenicline has also been shown to significantly delay smoking relapse. As the latest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of Varenicline has been reviewed in this paper.

AB - Varenicline, a partial agonist of α4β2 nicotinic acetylcholine receptor (nAChR), is the most recently approved drug for smoking cessation. Despite the availability of effective treatments for smoking cessation, such as nicotine replacement therapy and Bupropion sustained-release, abstinence rates remain less than optimal. As a nAChR partial agonist, Varenicline attenuates the craving and withdrawal symptoms that occur with abstinence from nicotine and also reduces the rewarding effects of nicotine obtained from smoking in patients who lapse. Clinical trials have demonstrated superior efficacy of this drug over Bupropion-SR for achieving abstinence from smoking, and Varenicline has also been shown to significantly delay smoking relapse. As the latest agent approved for smoking cessation, the mechanism of action, efficacy, and safety of Varenicline has been reviewed in this paper.

UR - http://www.scopus.com/inward/record.url?scp=67649616356&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=67649616356&partnerID=8YFLogxK

M3 - Review article

VL - 7

SP - 162

EP - 164

JO - Kathmandu University Medical Journal

JF - Kathmandu University Medical Journal

SN - 1812-2027

IS - 26

ER -

Rao J, Shankar PK. Varenicline: For smoking cessation. Kathmandu University Medical Journal. 2009 Apr 1;7(26):162-164.